Related Experiment Video
Updated: Oct 9, 2025
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
15.0K
New Indication for Ruxolitinib.
1Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .
The American Journal of Nursing
|December 23, 2021
Summary
Ruxolitinib, a kinase inhibitor, is now approved for treating chronic graft-versus-host disease. This approval offers a new therapeutic option for patients with this serious post-transplant complication.
Area of Science:
- Oncology
- Hematology
- Immunology
Background:
- Chronic graft-versus-host disease (cGVHD) is a significant complication following allogeneic stem cell transplantation.
- Existing treatments for cGVHD have limitations and can lead to significant morbidity.
Purpose of the Study:
- To evaluate the efficacy and safety of ruxolitinib for the treatment of chronic graft-versus-host disease.
Main Methods:
- A clinical trial was conducted to assess ruxolitinib's impact on cGVHD symptoms and patient outcomes.
- Data on treatment response, adverse events, and quality of life were collected.
Main Results:
- Ruxolitinib demonstrated significant efficacy in treating chronic graft-versus-host disease.
- The drug showed a manageable safety profile in the studied patient population.
Conclusions:
- Ruxolitinib is an effective new treatment option for patients with chronic graft-versus-host disease.
- This approval marks a significant advancement in managing this challenging condition.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
4.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.1K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.5K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:20The JAK-STAT Signaling Pathway
9.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.5K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
238
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
238
01:29Drugs for Treatment of Ulcerative Colitis in IBD
262
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
262